Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENT-31 Regimen Plus SBRT in EGFR-mutant Metastatic NSCLC (ORBIT)
NCT06775743Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Started Jan 2025; status: recruiting.
02
Drugs
sintilimabbevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06775743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775743.